Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2024-08-01 00:00:00 ET · period of report 2024-07-31 · accession 0001415889-24-020512 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-01 | 2024-07-31 | FENC | Raykov Rosty | CEO, Dir | A - Grant | $0.00 | +2,431 | 189.9K | +1% | $0 | |
| 2024-08-01 | 2024-08-01 | FENC | Raykov Rosty | CEO, Dir | S - Sale | $6.26 | -2,431 | 187.5K | -1% | -$15.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares | 2024-07-31 | A | A | 2,431 | $0.00 | 189,902 | D | — | — | (F1) Represents release of restriction from shares awarded 3-31-2023 |
| 2 | Common | Common shares | 2024-08-01 | S | D | 2,431 | $6.26 | 187,471 | D | — | — | (F2) Represents shares sold pursuant to a 10b5-1 plan dated December 14, 2023. |